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ABSTRACT
Impaired T-cell immune reconstitution is a major complication after allogeneic bone marrow transplantation
(BMT) and is particularly exacerbated in the setting of graft-versus-host disease (GVHD). Conventional
approaches to reduce GVHD, such as T-cell depletion or pharmacologic immunosuppression, typically fail to
enhance T-cell immunity and often further exacerbate this problem. An alternative strategy to mitigate GVHD
severity is the selective elimination of graft-versus-host–reactive donor T cells by using an incorporated
thymidine kinase suicide gene. This approach has been shown to effectively reduce GVHD, although the effect
of this strategy on T-cell reconstitution is unresolved. We addressed this question in a murine BMT model
(C57BL/6 [H-2b]3 AKR/J [H-2k]) in which donor and recipient differ at major and minor histocompatibility
antigens. Lethally irradiated AKR recipients transplanted with T cell–depleted bone marrow plus thymidine
kinase–positive T cells followed by post-BMT ganciclovir (GCV) administration had more prompt and
complete normalization of the T-cell repertoire than phosphate-buffered saline–treated GVHD control
animals. By 60 days after transplantation, mice administered GCV had T-cell repertoires that were virtually
indistinguishable from those of mice that underwent transplantation with T cell–depleted bone marrow alone
(no GVHD controls) when assayed by T-cell receptor (TCR) spectratyping. In contrast, phosphate-buffered
saline–treated animals had persistent skewing in most V families. T cells obtained from GCV-treated mice
also had significantly higher in vitro proliferative responses after posttransplantation inoculation with ovalbu-
min than GVHD animals, indicating that CD4 T-cell responses against a nominal antigen were better
preserved in these chimeras. Finally, GCV-treated mice had augmented immune reconstitution in response to
exogenous interleukin-7 administration, as evidenced by increased overall spleen cellularity and absolute
numbers of T and B cells. This was in contrast to GVHD control animals, which had a blunted response to
interleukin-7 administration. These data indicate that GVHD severity can be significantly reduced by selective
elimination of alloreactive donor T cells without compromise of T-cell immunity. Moreover, in light of
previous studies demonstrating that this strategy can reduce GVHD without loss of alloengraftment and
antileukemia reactivity, further examination of this approach in humans seems warranted.
© 2003 American Society for Blood and Marrow Transplantation
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wNTRODUCTION
Graft-versus-host disease (GVHD) is the primary
omplication associated with allogeneic bone marrow
ransplantation (BMT). One of the major problems
hat contributes to mortality in patients with GVHD i
42s impaired immune reconstitution, which predisposes
his patient population to potentially life-threatening
pportunistic infections (see review [1]). T-cell immu-
ity, in particular, is often compromised in patients
ith GVHD. This occurs as a consequence of thebone marrow transplantation
oi:10.1016/j.bbmt.2003.09.007mmunosuppressive therapy administered to treat this
complication and as the direct result of the graft-
versus-host (GVH) reaction that impairs thymic pro-
duction of new T cells and expansion of mature T cells
transferred in the donor marrow graft [2,3]. De-
creased thymic production of naive donor T cells
occurs as a result of direct epithelial cell damage in the
recipient thymus [4,5] along with reduced production
of the cytokines necessary for thymopoiesis (eg, inter-
leukin-7 [IL-7] and keratinocyte growth factor) [6,7].
Reconstitution of the mature T-cell compartment is
also adversely affected by the propensity of these cells
to have shortened survival in the periphery [8] and to
have limited T-cell receptor (TCR) repertoire diver-
sity [9]. Clinical strategies to reduce GVHD have
focused on the use of immunosuppressive agents that
nonspeciﬁcally affect T-cell function with the goal of
inhibiting GVH reactivity. Unfortunately, these
agents often further compromise T-cell immunity by
reducing absolute T-cell numbers or inhibiting the
function of existing donor T cells [10]. Another ap-
proach has been to employ ex vivo T-cell depletion to
reduce the severity of GVHD. Although this is effec-
tive in preventing GVHD, T-cell immunity is often
adversely affected because of the reduced number of
transferred mature T cells, which has a corresponding
deleterious effect on host immunity [11-13].
An alternative strategy to address the problem of
GVHD is to selectively eliminate only those donor T
cells that have antihost reactivity while sparing donor
T cells that are nonalloreactive. The approach that has
been most critically evaluated both in preclinical mod-
els [14,15] and in the clinic [16-19] has been incorpo-
ration of the thymidine kinase (TK) gene into donor
T cells so that these cells can then be targeted for
elimination after administration of the antiviral agent
ganciclovir (GCV). This strategy is based on the elim-
ination of dividing donor T cells early after transplan-
tation with the premise that most of these cells will be
GVH-reactive T cells responding to recipient alloan-
tigens [20]. The success of this approach, however, is
contingent on the retention of T-cell immune com-
petency in recipients after elimination of alloreactive
donor T cells. The purpose of this study was to ad-
dress this question in mice that had been protected
from lethal GVHD by GCV administration.
MATERIALS AND METHODS
Mice
C57BL/6 (B6; H-2b, Thy1.2) and AKR/J (H-2k,
Thy 1.1) mice (aged 4-16 weeks) were obtained from
The Jackson Laboratories (Bar Harbor, ME). TK
transgenic mice on a pure B6 background in which the
TK gene is targeted to the T cell by using a CD3
promoter/enhancer construct have been previously
described [21]. All animals were housed in the Amer-
ican Association for Laboratory Animal Care–accred-
ited Animal Resource Center of the Medical College
of Wisconsin. Mice received regular mouse chow and
acidiﬁed tap water ad libitum.
Reagents
GCV (Cytovene; Roche Laboratories, Nutley, NJ)
was dissolved in distilled water and stored in aliquots
at 20°C. GCV was thawed before use and adminis-
tered to animals intraperitoneally in phosphate-buff-
ered saline (PBS) at 50 mg/kg/d. Human recombinant
IL-7 was kindly provided by Dr. Toby Hecht (The
National Cancer Institute-Frederick, Frederick, MD).
IL-7 was reconstituted in PBS before administration
and was administered at 5 g/d to murine transplant
recipients.
Bone Marrow Transplantation
Bone marrow (BM) was ﬂushed from donor fe-
murs and tibias with Dulbecco modiﬁed Eagle me-
dium (DMEM) and passed through sterile mesh ﬁlters
to obtain single-cell suspensions. BM was T cell–
depleted in vitro with anti-Thy1.2 monoclonal anti-
body (clone 30-H12; rat immunoglobulin [Ig]G2b;
American Type Culture Collection, Rockville, MD)
plus low-toxicity rabbit complement (C-Six Diagnos-
tics, Mequon, WI). BM cells were washed and resus-
pended in DMEM before injection. Naive donor T
cells were obtained from transgenic animals by passing
erythrocyte-depleted spleen cells through nylon wool
columns to remove non-T cells. Host mice were con-
ditioned with lethal total body irradiation (1100 cGy)
administered as a single exposure at a dose rate of 67
cGy by using a Shepherd Mark I Cesium Irradiator
(J.L. Shepherd and Associates, San Fernando, CA).
Irradiated recipients received a single intravenous in-
jection of T cell–depleted (TCD) BM (107 cells) with
or without added TK T cells within 24 hours.
T-Cell Spectratype Analysis
Total RNA was prepared from mouse blood or
splenocytes by using Trizol (Gibco-BRL, Gaithers-
burg, MD) and converted to complementary DNA
(cDNA) as previously described [22]. Rearrangement
analysis was performed by polymerase chain reaction
(PCR) ampliﬁcation of the CDR3 by using V and C
region-speciﬁc primers [22,23]. The C-region primer
was labeled with ﬂuorescein, and the PCR products
were analyzed on denaturing polyacrylamide gels. The
ﬂuorescent PCR products were quantitated by using a
FluorImager (Molecular Dynamics, Sunnyvale, CA).
The gel data were collected as a 16-bit tagged image
ﬁle format ﬁle, and the intensities were analyzed with
ImageQuant software (Molecular Dynamics). The
analyses from splenocytes were performed on cDNA
samples that were titrated to ensure equal efﬁciency of
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ampliﬁcation of the TCR -chain cDNA constant
region. For calculation of CDR3 length changes, band
intensities originally measured as relative ﬂuorescence
units by the FluorImager were converted to the rela-
tive frequency (RF) of each band over the total band
intensity. The relative band intensities correct for mi-
nor ﬂuctuations in the data. To represent the large
data sets generated, we used a graphic representation
of differences between control and experimental spec-
tratypes by generating comparative RF plots [24]. For
2 nearly identical spectratype distributions, a compar-
ative RF plot yields a diagonal. If the distributions are
symmetric, the leading points fall close to the trailing
points because of the Gaussian distribution. If the
distributions are very different, however, the plots will
balloon, and the tracings may cross. For each data set,
we generated an average diagonal for the control
group that underwent transplantation with TCD BM
only (no-GVHD group). This was used as 1 dimen-
sion in all ensuing plots. The entire plot of an exper-
imental data set was reduced to a point by taking the
square root of the sum of the square of the differences
between the data set and the BMT control values.
This represents the skew of the experimental data set.
Ovalbumin Inoculation
Ovalbumin (OVA) was dissolved in PBS, and the
concentration was quantitated on an Eppendorf Bio-
photometer (Brinkmann Instruments, Westbury, NY)
at 280 nm. Mice were then inoculated subcutaneously
at the base of the tail with 100 g of OVA (Pierce,
Rockford, IL) in 100 L of complete Freund adjuvant.
Proliferation Assays
Spleen cells were harvested from OVA-inoculated
and control animals. Red blood cells were removed by
hypotonic lysis. Spleen cells were seeded at a concen-
tration of 2  105 cells per well in complete DMEM
and 10% fetal bovine serum in the presence of soluble
anti-CD3 antibody (clone 145-2C11; 1 g/mL) or
OVA (75 g/mL). Cells were cultured for either 3
days (anti-CD3 antibody) or 5 days (OVA). One mi-
crocurie of [3H]thymidine was added to wells for the
ﬁnal 12 to 18 hours before harvest. Cells from tripli-
cate wells were harvested, and proliferation was as-
sessed by using a liquid scintillation counter (Micro-
medics Systems, Huntsville, AL). Control wells
consisted of cells cultured in the absence of either
anti-CD3 or OVA. Data are presented as the  counts
per minute (ie, average counts per minute of triplicate
experimental wells minus average counts per minute
of triplicate control wells) and were normalized for the
percentage of CD3 T cells in the spleens of each
animal.
Flow Cytometric Analysis and Assessment of
Chimerism
Monoclonal antibodies conjugated to either ﬂuo-
rescein isothiocyanate (FITC) or phycoerythrin (PE)
were used to assess chimerism in marrow transplant
recipients. PE anti-CD8 (clone CT-CD8a; rat IgG2a)
was obtained from Caltag (San Francisco, CA). PE
anti-TCR  (clone H57-597; hamster IgG), PE anti-
CD4 (clone GK1.5; rat IgG2b), FITC anti-Thy1.2
(clone 30-H12; rat IgG2b), FITC anti–Gr-1 (clone
RB6-8C5; rat IgG2b), and FITC anti–H-2Kb (clone
AF6-88.5; mouse IgG2a) were all purchased from
Pharmingen (San Diego, CA). Spleen and thymus
cells were obtained from chimeras at deﬁned intervals
after transplantation, processed into single-cell sus-
pensions, and stained for 2-color analysis. Red blood
cells were removed when necessary by hypotonic lysis.
Cells were analyzed on a FACScan ﬂow cytometer
(Becton-Dickinson, Mountain View, CA). At least
10000 cells were analyzed for each determination
whenever possible.
Statistics
Survival curves were constructed by using the
Kaplan-Meier product-limit estimator and compared
by using the log-rank rest. Group comparisons of
thymidine incorporation in proliferation assays and
absolute cell numbers in IL-7 experiments were per-
formed by using the Mann-Whitney U test. A P value
.05 was deemed to be signiﬁcant in all experiments.
RESULTS
TCR Repertoire Analysis in Murine Transplant
Recipients
Individual spectratypes derived from tissue sam-
ples of mice that have undergone allogeneic marrow
transplantation are often analyzed by visual inspec-
tion. The lack of quantitation generally associated
with this approach can make the comparative assess-
ment of repertoire differences among multiple groups
problematic. In an effort to circumvent this problem,
we used an approach in which diagonal RF plots were
constructed to quantify the RF distributions of indi-
vidual bands from spectratypes derived from individ-
ual mice. To illustrate this approach, lethally irradi-
ated AKR mice underwent transplantation with TCD
B6 BM alone. These mice do not develop GVHD
because of the absence of mature donor T cells in the
marrow graft. Animals were killed on day 37, and
spleen cells were obtained for TCR spectratype anal-
ysis. The band intensities of 2 spectratype gels gener-
ated from cDNA obtained from the spleens of these
mice (Figure 1A and C) were converted into an RF,
which is the intensity of the band divided by the sum
of all intensities. The RF values for equivalent bands
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from the 2 gels were then plotted as a single point
(Figure 1B). These data show a symmetric distribution
within the V family, as evidenced by the fact that all
points fall on the diagonal. Another indicator of sym-
metry is the fact that points from the rising part of the
distribution overlap with those from the descending
part of the distribution because of the normal Gauss-
ian distribution of bands within most V families.
This distribution is identical to what is observed in
normal nontransplanted B6 mice (data not shown).
Therefore, these data indicate that in mice that are
free from GVHD, a linear diagonal representation is
the expected plot.
Comparative Analysis of T-Cell Repertoires in
Blood and Spleen of GVHD Recipients
We next applied this approach to TCR repertoire
analysis in mice undergoing GVHD. Prior studies
have indicated that the evaluation of repertoire diver-
sity is inﬂuenced by the source of tissue [25,26], indi-
cating that spectratypes generated from different tis-
sue sources may not necessarily yield concordant
results. To examine this question in our model, we
analyzed blood and spleen cell samples that were con-
currently obtained from lethally irradiated AKR mice
who underwent transplantation with TCD B6 BM
plus 5  105 TK T cells. This T-cell dose is sufﬁ-
cient to cause clinically signiﬁcant GVHD in non–
GCV-treated mice [27]. Transplanted animals were
bled 37 days after transplantation and then killed
within 24 hours to obtain spleen cells for analysis.
Spectratype studies revealed 2 different patterns. In
some families (Figure 2, panels 1 and 2), signiﬁcant
skewing was visible in the spleen, whereas the reper-
toire in the blood was relatively normal. Alternatively,
in other animals, represented by data shown in panel
3, skewing was visible in both blood and spleen but
was much more pronounced in the spleen. Overall,
spectratype analysis using blood as the source of the
sample tended to underestimate the degree of reper-
toire skewing. Therefore, in subsequent studies, we
performed TCR repertoire analyses on cDNA sam-
ples obtained from spleen cells as a more accurate
reﬂection of repertoire complexity.
GCV-Treated Mice Are Able to Reconstitute a
Complex T-Cell Repertoire
Studies were then conducted to assess the effect of
GCV administration on reconstitution of the T-cell
repertoire in mice that were protected from lethal
GVHD. Irradiated AKR mice underwent transplanta-
tion with TCD B6 BM alone (no-GVHD control) or
together with 5  105 TK T cells. Mice that under-
went transplantation with TK T cells were treated
with either PBS (GVHD control) or GCV on days 1
to 10 after transplantation. Animals from these 3
groups were then killed on either day 37 or day 62
after transplantation. Serial weight curves indicated
that GCV-treated mice had higher weights, indicative
Figure 2. Analysis of spleen cells is a more sensitive indicator of
TCR repertoire complexity than peripheral blood in GVHD mice.
Lethally irradiated (1100 cGy) AKR mice underwent transplanta-
tion with TCD B6 BM together with 5  105 TK T cells.
Representative mice were bled 37 days after transplantation and
then killed within 24 hours to obtain spleen cells for determination
of TCR repertoire complexity. Data show repertoire complexity
and skewing in representative V families after analysis of periph-
eral blood (B) and spleen cells (S) obtained from 3 individual mice.
Data from individual mice are partitioned by vertical lines.
Figure 1. Generation of diagonal relative frequency (RF) plots.
Lethally irradiated (1100 cGy) AKR mice underwent transplanta-
tion with TCD B6 BM and were then killed 37 days after trans-
plantation. RNA was extracted and cDNA generated from spleen
cells obtained from 2 chimeras. CDR3 spectratype analysis was then
performed on cDNA samples. Data shown in panels A and C
represent spectratypes from the V5.1 family derived from individ-
ual mice. RF values for equivalent bands from the 2 gels are shown
in panel B.
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of protection from GVHD (Figure 3A and B). This
was most pronounced at day 62 but was also evident
37 days after BMT. Analysis of spleen cell chimerism
demonstrated that mice in all 3 groups were fully
engrafted with donor T cells at the time TCR reper-
toire analysis was performed (Figure 3C), indicating
that only donor T cells were being evaluated.
The extent of repertoire skewing was analyzed by
spectratype analysis. An example of the data obtained
is shown in Figure 4A for the V5.1 family analyzed in
2 mice. Pronounced skewing in the spleens of GVHD
mice (PBS treated) was observed 37 days after trans-
plantation and was also evident at day 62. GCV-
treated animals showed less skewing at day 37, and by
day 62, the pattern was similar to that of the TCD BM
control animals. The data for all the animals in an
experimental group are shown in the form of diagonal
RF plots for the V5.1 family (Figure 4B) and the
V11 family (Figure 4C). For each animal and each
V family, the spectratype band RF is plotted against
the average RF of the TCD BM mice (controls). The
latter mice generated tight diagonal plots with clus-
tered data points, indicating nearly identical and sym-
metric distributions. Mice receiving TK T cells and
PBS had skewed repertoires at both time points, as
shown by the ballooning and crossing graphs. Al-
though the GCV-treated mice showed some early
skewing, by day 62, the graphs were tighter and on the
diagonal for both the families.
A single measure for the skew was obtained by
calculating the deviation of each point in the RF plot
from the average of the control (TCD BM) data set.
The square root of the sum of the squares of the
deviations was used as the skew value. This allowed a
composite analysis of all the V families at both time
points and under both conditions (Figure 5). The
shaded region below a skew of 0.1 indicates the mean
(0.051) and 2 SD (0.023) of the control data and
represents the background noise in the measurements.
The data show that for the untreated mice (Figure
5A), all but 1 of the skew values started above the
controls and that the skew increased at day 62 except
for 2 families (V5.1 and 6), for which the skew stayed
the same. For the GCV-treated animals, the skewing
at 37 days was reduced relative to the untreated mice
(Figure 5B). By day 62, all but 1 of the families showed
spectratype patterns that fell in the control range.
Collectively, these data indicate that GCV-treated an-
imals were protected from severe GVHD and thus
able to reconstitute a normal complex T-cell reper-
toire.
T Cells from GCV-Treated Mice Are Able to
Respond to a Nominal Antigen
One of the primary immune deﬁcits in allogeneic
marrow transplant recipients is impaired reconstitu-
tion of CD4 T cells, which has been shown to cor-
relate with the development of infectious complica-
tions [12]. The T-cell response to exogenous
administration of the nominal antigen OVA is prefer-
entially mediated by CD4 T cells, and, therefore,
this serves as an experimental approach to assess the
extent of CD4 T-cell reconstitution in marrow
transplant recipients. To examine CD4 T-cell re-
constitution, lethally irradiated AKR mice underwent
transplantation with either TCD B6 BM alone or
together with 5 105 TK T cells. Mice transplanted
with T cells were treated with either PBS or GCV on
days 1 to 10, as described previously. Animals in all
groups were then immunized with OVA in complete
Figure 3. GCV administration protects animals with transplants from severe GVHD. Lethally irradiated (1100 cGy) AKR mice underwent
transplantation with TCD BM alone (E; n 3 per group) or together with 5 105 TK T cells. Animals that underwent transplantation with
TK T cells were then treated with either PBS (; n  4-5 per group) or GCV (; n  5-6 per group) for 10 days beginning on day 1 after
transplantation. Mean serial weight measurements are shown for the ﬁrst 37 days (A) and 62 days (B) in 2 separate experiments. All mice in
panel A survived until day 37. Two of 5 GVHD and 4 of 6 GCV-treated animals survived until day 62 (B). The mean percentage of donor
T cells in the spleens of transplanted animals at the time they were killed is shown in panel C. Actual values 	 1 SEM for percentage of donor
T cell engraftment were as follows—day 37: BM, 86 	 1; GVHD, 100 	 0; and GCV, 98 	 1; day 62: BM, 93 	 1; GVHD, 100 	 0; and
GCV, 100 	 0.
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Freund adjuvant on days 32 to 45 after transplanta-
tion. Thirty days after primary inoculation, mice were
killed, and harvested spleen cells were rechallenged in
vitro with OVA. As a positive control for T-cell pro-
liferation, spleen cells were also stimulated with solu-
ble anti-CD3 antibody. There was no statistically sig-
niﬁcant difference in the amount of thymidine
incorporation after anti-CD3 stimulation between any
of the 3 groups of animals (Figure 6), indicating that T
cells in all cohorts were not anergic. In contrast, thy-
midine incorporation after OVA stimulation was sig-
niﬁcantly lower in PBS-treated mice when compared
with either TCD BM control (P  .0007) or GCV-
Figure 4. Selective elimination of alloreactive donor T cells results
in normalization of the T-cell repertoire. Lethally irradiated (1100
cGy) AKR mice underwent transplantation with TCD B6 BM alone
or together with 5  105 TK T cells. Mice that underwent
transplantation with TK T cells were treated with either PBS or
GCV on days 1 to 10 after BMT. Cohorts of mice were killed on
days 37 and 62 after transplantation, and spleen cells were analyzed
by CDR3 spectratyping. A, V5.1 spectratypes from 2 of the mice
that had received TCD BM only, TCD BM plus TK T cells
(PBS), or TCD BM and TK T cells followed by GCV adminis-
tration (GCV), respectively. Repertoire skewing can be easily ob-
served in the experimental animals that had received TK T cells
without GCV. Skewing is graphically visualized in the bottom
panels by using diagonal RF plots for the V5.1 (B) and the V11
(C) families on days 37 and 62 after BMT. The relative frequency
(RF) of bands from the individual mice is plotted against the average
RF from 3 mice that received TCD BM alone. These latter mice
represent mice with normal repertoire development.
Figure 5. Composite repertoire skew analysis for 20 representative
V families in PBS- and GCV-treated mice. Repertoire skew is
calculated from diagonal RF plots as described in Materials and
Methods. A, Cumulative results from mice (2-3 per group) that
underwent transplantation with TCD BM plus TK T cells and
that were treated with PBS for 10 days. B, Results from mice that
underwent transplantation with TCD BM plus TK T cells and
that were then administered GCV for 10 days. The shaded values
below 0.1 represent the range observed for mice that underwent
transplantation with TCD BM alone and served as controls for
these experiments.
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treated animals (P  .038; Figure 6). There was no
difference in proliferation to OVA between TCD BM
controls and GCV-treated animals (P  .75). There
was also no statistically signiﬁcant difference in the
mean percentage of CD3 CD4 T cells in TCD,
GVHD, and GCV-treated animals (18.8%, 18.7%,
and 17.4%, respectively), indicating that the lack of
responsiveness to OVA in GVHDmice was not due to
a quantitative reduction of CD4 T cells in the cul-
ture. These studies demonstrated that GCV adminis-
tration did not compromise the ability of CD4 T
cells from GVHD-protected mice to respond to a
nominal antigen.
IL-7 Augments T- and B-Cell Reconstitution in
GCV-Treated Mice
IL-7 is a cytokine that has been shown to enhance
immune reconstitution after allogeneic marrow trans-
plantation in mice that have undergone transplanta-
tion with TCD BM alone or after syngeneic BM, but
it has been ineffectual in animals with GVHD [28,29].
Because GCV administration preferentially spares
nonalloreactive donor T cells in mice undergoing
GVHD, the administration of IL-7 to GCV-treated
mice is a potential strategy to augment T-cell recon-
stitution in GVHD-protected animals after BMT. Ad-
ditionally, IL-7 has been shown to enhance B-cell
proliferation [30] and induce expansion of myeloid
progenitor populations [31,32], suggesting that in the
absence of GVHD, IL-7 might have other potentially
salutary effects with respect to immune reconstitution
after BMT. To examine the effects of IL-7 in GVHD
versus GCV-treated animals, experiments were per-
formed in which lethally irradiated AKR mice under-
went transplantation with TCD B6 BM plus 5  105
TK T cells and then were administered either PBS
or GCV to eliminate alloreactive donor T cells, as
described previously. To assess the effect of IL-7 on
immune reconstitution, mice in both experimental
groups were treated with either PBS or IL-7 (5 g/d)
on days 19 to 28 after BMT. Before administration of
PBS or IL-7, all mice were bled and conﬁrmed to have
complete donor T-cell engraftment (mean of 93%
donor T cells in all groups). GCV-treated mice had
signiﬁcantly higher absolute numbers of spleen cells,
donor T cells, B cells, and granulocytes when com-
pared with PBS-treated GVHD control animals (Fig-
ure 7). The administration of IL-7 after BMT to
GVHD mice, however, resulted in no statistically sig-
niﬁcant increase in any of these end points when
compared with GVHDmice that did not receive IL-7.
In contrast, the administration of IL-7 to GCV-
Figure 6. Effect of GCV treatment on the donor T-cell response to posttransplantation immunization with a nominal antigen. Lethally
irradiated (1100 cGy) AKR mice underwent transplantation with TCD B6 BM alone (n  6) or together with 5  105 B6 TK T cells. Mice
that underwent transplantation with TK T cells were treated with either PBS (n  8) or GCV (50 mg/kg; n  8) on days 1 to 10 after BMT.
On days 32 to 45, mice were immunized with OVA as described in Materials and Methods. Thirty days after immunization, mice were killed,
and spleen cells were stimulated in vitro with either soluble anti-CD3 antibody (CD3) or OVA for 3 or 5 days, respectively. Data are presented
as the mean thymidine incorporation counts per minute (cpm) 	 1 SEM from individual animals. Thymidine incorporation was normalized
for the percentage of CD3 T cells present in each of the wells at the time of culture. Data are cumulative results derived from 2 independent
experiments. Statistics are as follows–CD3: BM versus PBS, P  .14; BM versus GCV, P  .49; PBS versus GCV, P  .38; OVA: BM versus
PBS, P  .0007; BM versus GCV, P  .75; PBS versus GCV, P  .038.
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treated mice signiﬁcantly augmented the absolute
number of spleen cells, donor T cells, and B cells, but
not granulocytes. Collectively, these data indicate that
posttransplantation GCV administration augmented
immune reconstitution relative to PBS-treated
GVHD control mice and that elimination of host-
reactive donor T cells by GCV conferred responsive-
ness to the immune-enhancing effects of IL-7.
DISCUSSION
The process of T-cell reconstitution after alloge-
neic BMT can be conceptualized as the engraftment
and subsequent expansion of both alloreactive and
nonalloreactive donor T cells. During GVHD, there
is a dominance of host-reactive donor T cells that can
both skew and contract the T-cell repertoire, resulting
in limited repertoire diversity [33]. Additionally,
GVHD results in lymphoid hypoplasia, which signif-
icantly reduces the absolute number of B and T cells
that are capable of mediating effective immune re-
sponses. This combination of events is largely respon-
sible for the increased susceptibility of GVHD pa-
tients to opportunistic infections. The challenge in the
clinical setting is to reduce the severity of GVHD
without simultaneously compromising effective T
cell–mediated immune responses. Clinical approaches
that have been most extensively examined are the use
of nonspeciﬁc immunosuppressive agents and ex vivo
T-cell depletion. Both, however, suffer from the fact
that T-cell immunity is, in most patients, adversely
affected because of inhibition of global T-cell function
and quantitative reductions in overall T-cell numbers.
We have reasoned that an effective strategy to address
this clinical problem is one in which alloreactive do-
nor T cells are preferentially eliminated early after
transplantation with the intention of sparing nonallo-
reactive donor T cells that have the capacity to affect
other important immune functions. We have previ-
ously shown that this approach is an effective way to
reduce GVHD severity without compromise of either
alloengraftment [21] or graft-versus-leukemia reactiv-
ity [34].
In this study, we have extended these observations
by examining the effect of this strategy on T-cell
reconstitution. Overall, our data demonstrate that
host-reactive donor T cells can be eliminated early
after BMT without compromising the ability of the
recipient to reconstitute functional T-cell immunity.
A characteristic of GVHD is that there are typically
abnormalities in the T-cell repertoire that manifest as
skewing and contraction of speciﬁc V families
[35,36]. This has been demonstrated both in the pe-
ripheral blood [30] and in selected GVHD target
organs [26,37]. In some studies, there has also been an
association between an abnormal T-cell repertoire
and a lack of immune responsiveness to infectious
agents [33], suggesting that normalization of the rep-
ertoire is one factor that contributes to effective post-
transplantation immunity. Comparative assessment of
the TCR repertoire, however, can be problematic
because of the number of V families and the multi-
plicity of clonotypes within each family that constitute
the full repertoire. Most studies have used qualitative
comparisons to assess the repertoire, but this does not
always provide a comprehensive assessment of reper-
toire complexity. To that end, we used a quantitative
methodology [22] to assign a value for skewing away
from an empirically deﬁned control repertoire (TCD
BM alone). The data showed that in the animals
treated with PBS in which GVHD was observed, the
repertoires were skewed both early and late after
transplantation (Figure 5). Mice treated with GCV
showed lower levels of skewing at day 37, and for
almost all the V families, this decreased to control
Figure 7. IL-7 differentially augments immune reconstitution in
GCV versus PBS-treated mice. Lethally irradiated (1100 cGy) AKR
mice underwent transplantation with TCD B6 BM (107 cells) to-
gether with 5  105 TK T cells. Mice were then treated with
either PBS or GCV (50 mg/kg) on days 1 to 10 after BMT. Cohorts
of mice from each treatment group were administered either PBS or
IL-7 (5 g/d) for 10 days beginning on day 19 after transplantation.
Mice were killed on day 30, and spleens were analyzed for overall
spleen cellularity and absolute numbers of donor B cells, T cells,
and granulocytes. Data are shown as mean values 	 1 SEM and are
derived from 2 independent experiments. *P 
 .01, GCV versus
PBS group; **P 
 .05, GCV IL-7 versus GCV group.
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levels by day 62. AKR mice delete a number of V
families (V 5, 6, 8, 9, 11, and 12) because of thymic
responses to viral superantigens, whereas B6 mice do
not delete these families. The reconstituted reper-
toires in the GCV-treated mice showed a B6 pattern
of intensities for these V families, indicating that the
T cells were of B6 marrow origin and that sufﬁcient
donor-derived antigen-presenting cells had entered
the thymus to obviate the I-E–dependent deletion
that occurs in AKR animals. From this we conclude
that the normalization of repertoires in GCV-treated
mice was due to the emergence of BM-derived donor
T cells that are tolerant to host alloantigens. However,
in GVHD animals (PBS treated), thymic damage in-
duced by alloreactive donor T cells hindered the
emergence of new T cells, resulting in a perpetuation
of repertoire skewing.
When tested in functional assays, donor T cells
from mice in all groups responded equally well to
stimulation with anti-CD3 antibody when normalized
for T-cell content in individual wells. These data
indicated that T cells from all 3 cohorts were not
anergized but remained able to respond to a poly-
clonal stimulus. A central problem in immunity after
BMT, however, is the markedly impaired reconstitu-
tion of CD4 T cells, particularly in the setting of
GVHD. This results in compromised cellular and
humoral immunity. We examined CD4 T-cell func-
tion in GCV-treated mice by inoculating with OVA,
an exogenous protein presented by antigen-presenting
cells to CD4 T cells. We observed that splenic T
cells obtained from GCV-treated mice had signiﬁ-
cantly higher proliferative responses when compared
with T cells from mice undergoing GVHD. Because
the percentage of CD4 T cells was the same in wells
containing spleen cells from GCV-treated and
GVHD control animals, this was evidence that CD4
T-cell function was qualitatively impaired in the latter
mice. TCR spectratype studies demonstrated that the
T-cell repertoire was markedly skewed in GVHD
mice during the time that mice were inoculated with
OVA (Figures 4 and 5). We infer from these data that
the clonotypes represented by the skewed bands were
responding to alloantigenic differences and therefore
were not capable of responding to a nominal antigen.
Conversely, the more diverse repertoire present in
GCV-treated mice rendered these mice more compe-
tent to respond to a previously unencountered anti-
genic stimulus.
A number of murine studies have demonstrated
that administration of IL-7 can enhance lymphocyte
recovery in murine recipients undergoing BMT
[28,29,38]. This has been attributed to augmentation
of thymopoiesis, as well as expansion of mature pe-
ripheral T cells [39]. The immune-restorative prop-
erties of IL-7, however, have not been observed in
mice undergoing GVHD [28,29], indicating that IL-7
treatment may not be a viable strategy to augment
immune reconstitution in this setting. T-cell recon-
stitution in animals that underwent transplantation
with TCD BM alone is attributable exclusively to the
generation of BM-derived donor T cells arising after
selection in the thymus. In contrast, both mature do-
nor T cells not eliminated by GCV and BM-derived
donor T cells can contribute to host immunity in
GCV-treated animals [21]. This distinction is of po-
tential clinical importance. The risk of acquiring an
opportunistic infection is highest early in the post-
transplantation period. Therefore, the capability of
mounting an effective T-cell response may be impor-
tant in preventing infectious complications during this
period [40]. Early after transplantation, T-cell immu-
nity is primarily dependent on mature T cells that are
transferred in the marrow graft. The generation of
new BM-derived donor T cells, in contrast, occurs
over time to supplement T-cell reconstitution, al-
though in adults, this process is retarded and con-
strained by direct thymic damage from the condition-
ing regimen, age-related involution, or both [41-43].
In these patients, mature T cells assume the primary
role in T-cell immunity because of limited thymic
production of new T cells. The ability to attenuate
GVHD and preserve mature T cells that can respond
to an immunorestorative cytokine, such as IL-7, may
therefore be therapeutically advantageous. Our data
indicate that post-BMTGCV administration can con-
fer responsiveness to the immune-enhancing effects of
IL-7, as evidenced by increased overall spleen cellu-
larity and absolute numbers of donor T and B cells.
Therefore, sequential administration of GCV fol-
lowed by IL-7 may be a viable strategy to augment
immune reconstitution after allogeneic marrow trans-
plantation, particularly in older patients in whom thy-
mic production is more limited.
The application of this approach to humans, how-
ever, may be more challenging because of current
technical limitations regarding the efﬁciency of gene
transfer. The use of transgenic TK T cells ensures
that each mature alloreactive T cell is potentially ca-
pable of being eliminated by the administration of
GCV. In contrast, existing clinical transduction ap-
proaches do not result in transfer of the TK gene into
all targeted T cells [16-19]. Therefore, control of
GVHDmay be less effective and immune competency
less robust in a setting in which residual alloreactive
donor T cells that are not susceptible to elimination
by GCV are able to persist in the recipient. The extent
to which this may represent a signiﬁcant clinical lim-
itation remains to be determined and will also be
contingent on ongoing technological improvements
designed to enhance gene transfer in targeted T-cell
populations.
In summary, these studies demonstrate that
GVHD severity can be substantially attenuated by
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using a genetic approach in which alloactivated donor
T cells are selectively eliminated from recipient mice
early after transplantation. This strategy results in
enhanced T-cell reconstitution, indicating that elimi-
nation of GVH-reactive donor T cells allows residual
mature and BM-derived donor T-cell populations to
emerge and maintain functional T-cell competency.
We conclude that, in light of previous studies dem-
onstrating that this strategy can also result in preser-
vation of alloengraftment and antileukemia reactivity,
further examination of this approach in humans seems
warranted.
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